Acute Myelogenous Leukemia
Showing 1 - 25 of >10,000
Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous
Recruiting
- Breast Cancer
- +4 more
- Web bases survey
-
Canton, OhioCleveland Clinic Mercy Hospital
Aug 2, 2023
Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous
Recruiting
- Breast Cancer
- +4 more
- Web based survey
-
New Haven, Connecticut
- +6 more
Aug 8, 2023
Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in Minneapolis (N-803)
Completed
- Acute Myelogenous Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Jan 4, 2023
Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Relapsed, Adult, Acute Myelogenous Leukemia, Adult Trial in
Terminated
- Acute Myelogenous Leukemia in Relapse
- +4 more
-
Tucson, Arizona
- +12 more
Aug 18, 2022
Acute Myeloid Leukemia Trial in Ramat Gan (CAR-T CD19)
Recruiting
- Acute Myeloid Leukemia
- CAR-T CD19
-
Ramat Gan, IsraelChaim Sheba Medical Center
Oct 30, 2022
Venetoclax Tablets Crushed and Dissolved Into a Solution
Not yet recruiting
- Hematologic Malignancy
- +18 more
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Nov 8, 2023
LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of
Completed
- Leukemia, Myelogenous, Acute
-
Charlotte, North CarolinaLevine Cancer Institute
Apr 19, 2022
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)
Active, not recruiting
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Gemtuzumab Ozogamicin
-
Valhalla, New YorkNew York Medical College
Sep 26, 2022
MDS (MDS), Acute Myelogenous Leukemia (AML) Trial in United States (low dose 5'-azacitidine)
Active, not recruiting
- Myelodysplastic Syndromes (MDS)
- Acute Myelogenous Leukemia (AML)
- low dose 5'-azacitidine
-
Basking Ridge, New Jersey
- +6 more
Dec 1, 2022
Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia Trial in Tianjin (LILRB4 STAR-T cells injection)
Not yet recruiting
- Acute Myelogenous Leukemia
- Chronic Myelomonocytic Leukemia
- LILRB4 STAR-T cells injection
-
Tianjin, Tianjin, China
- +1 more
Feb 12, 2023
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia Trial in Minneapolis (biological, drug,
Not yet recruiting
- Acute Myelogenous Leukemia
- +17 more
- Peripheral Blood Stem Cell Transplant
- +7 more
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Mar 27, 2023
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, MDS Trial in Tucson (Bendamustine, Cyclophosphamide)
Recruiting
- Acute Lymphoblastic Leukemia
- +12 more
-
Tucson, ArizonaThe University of Arizona Cancer Center
Dec 13, 2022
Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +2 more
- RD13-02 cell infusion
-
Xuzhou, Jiangsu, ChinaAffiliated hospital of Xuzhou medical college
Jun 7, 2023
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) Trial in United States
Recruiting
- Acute Myelogenous Leukemia (AML)
- +5 more
- Conditioning Chemotherapy
- Cord blood graft
-
Basking Ridge, New Jersey
- +6 more
May 22, 2023
Acute Myelogenous Leukemia, AML Trial in Worldwide (Venetoclax, Cytarabine)
Completed
- Acute Myelogenous Leukemia
- AML
-
Kansas City, Kansas
- +8 more
Aug 3, 2022
AML, B-ALL, T-ALL Trial in Memphis (CD123-CAR T, Cyclophosphamide, Fludarabine)
Recruiting
- AML
- +4 more
- CD123-CAR T
- +4 more
-
Memphis, Tennessee
- +1 more
May 10, 2022
Acute Myelogenous Leukemia, MDS Trial in Shanghai (Gentulizumab)
Recruiting
- Acute Myelogenous Leukemia
- Myelodysplastic Syndromes
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Feb 22, 2022
Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia Trial run by the NHLBI (T-cell replete
Completed
- Myeloproliferative Disorders
- +4 more
- T-cell replete PBPC allograft
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 12, 2022
Acute Myelogenous Leukemia (AML) Trial in Australia (MAX-40279)
Recruiting
- Acute Myelogenous Leukemia (AML)
-
Darlinghurst, New South Wales, Australia
- +3 more
Jan 18, 2022
Pediatric Acute Myelogenous Leukemia (AML) Trial in Australia, Canada, United States (Decitabine)
Terminated
- Pediatric Acute Myelogenous Leukemia (AML)
-
Phoenix, Arizona
- +21 more
Jun 24, 2022
High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston
Completed
- High Risk Myelodysplastic Syndrome
- +2 more
- Daratumumab
-
Houston, TexasM D Anderson Cancer Center
Nov 21, 2022
Acute Myeloid Leukemia Trial in Los Angeles, San Francisco (Azacitidine, Tagraxofusp-erzs)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- Tagraxofusp-erzs
-
Los Angeles, California
- +1 more
Jan 31, 2023
Acute Myeloid Leukemia (AML) Trial in Leipzig (VEN+AZA-5)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
-
Leipzig, GermanyUniversitätsklinikum Leipzig, Klinik und Poliklinik für Hämatolo
Apr 25, 2023
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Trial in Oklahoma City, Houston (Fenretinide,
Terminated
- Acute Myelogenous Leukemia
- +2 more
- Fenretinide
- +2 more
-
Oklahoma City, Oklahoma
- +1 more
Mar 17, 2022